ArticleMedicine2026
Trends in mortality rates of female breast cancer in China, 2004 to 2021.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in breast cancer mortality and analysis of years of life lost among Chinese residents, 2013-2021.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
National-wide estimates of female breast cancer (BC) mortality rates in China are largely derived from the global burden of disease study or global cancer statistics, population-based surveillance data remain scarce. The current study aims to analyze the trend changes of female BC mortality rates from 2004 to 2021 and to inform targeted control strategies. Age-specific deaths and mortality rates from 2004 to 2021 were extracted from the Chinese Cause-of-Death Surveillance Dataset. Joinpoint regression model was applied to explore the trend changes with average annual percent change (AAPC) in mortality rates. A total of 108,063 occurred due to female BC from 2004 to 2021. The crude mortality rate (CMR) (AAPC = 2.21%) showed an increased trend and the age standard mortality rate (AAPCChina = 0.68%, AAPCworld = -0.29%) remained relatively stable from 2004 to 2021. Despite higher CMR in urban areas, the absolute urban deaths were fewer. Both urban and rural areas experienced an upward trend in CMR (AAPCurban = 1.08%, AAPCrural = 3.13%). The age standard mortality rate in urban and rural areas remained relatively stable (AAPCurban = -0.13%, AAPCrual = 1.35%). Age-stratified analysis showed the CMR remained relatively stable in females, whereas urban females at age of 0 to 24 years (AAPC = 26.98%) and rural females exhibited significant increases at ages of 25 to 34 years (AAPC = 2.31%), 35 to 64 years (AAPC = 0.80%), ≥65 years (AAPC = 1.01%). Expanding screening coverage in rural areas and improving the accessibility of BC screening and treatment for the elderly can effectively enhance the utilization of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.